Artemis International, an ingredient supplier specializing in berry nutraceuticals, has become the sole U.S. distribution partner for innoVactiv’s InSea2, a seaweed-based ingredient for glucose control.

The partnership highlights the company’s expansion beyond its berry portfolio to deliver a more diverse and integrated range of functional ingredients. Other recent offerings include functional mushroom and botanical ingredients.

InSea2 is derived from brown seaweeds sustainably harvested in the North Atlantic Ocean and manufactured in Canada under strict standards; it’s supported by eight human clinical trials, all focused on blood sugar management and metabolic health, the company reported.

As the number of people contending with obesity and diabetes continues to increase, blood sugar management has become a central focus in the U.S. InSea2 acts on two digestive enzymes that convert dietary carbohydrates into glucose. This dual action mechanism significantly reduces glycemic response from the first use while also providing long-term benefits, the company reported.

“We are thrilled to be working with innoVactiv and this amazing ingredient,” said Leslie Gallo, president of Artemis International. “We strive to find unique, innovative ingredients that provide natural solutions to health issues, and alternatives to pharmaceuticals. Blood sugar regulation remains a significant issue for so many, and InSea2 has the science showing just how powerful it is in reducing blood sugar spikes and improving overall metabolic health, one of the keys to longevity.”

“This partnership with Artemis is rooted in shared values and common drivers, a strong commitment to science, meaningful differentiation, deep ingredient expertise, and a dedication to improving people’s well-being,” said Patrice Dionne, CEO of innoVactiv. “With 115 million Americans affected by prediabetes, partnering with Artemis enables us to expand access to our science-backed InSea2 and support individuals seeking to maintain healthy blood glucose levels.”